Atrial Fibrillation Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies

May 08 21:30 2023
Atrial Fibrillation Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 15+ key pharma and biotech companies are working on 15+ pipeline drugs in the Atrial Fibrillation therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Atrial Fibrillation Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Atrial Fibrillation Market. 

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Atrial Fibrillation Pipeline Analysis

Atrial Fibrillation Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Atrial Fibrillation and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous

  • Subcutaneous

  • Oral

  • Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal antibody

  • Small molecule

  • Peptide

Mechanism of Action of the Emerging Therapies 

  • Acetylcholine inhibitors

  • Ion channel antagonists

  • Undefined mechanism

  • Beta-adrenergic receptor antagonists

  • Beta 1;2 adrenergic receptor antagonists

  • Thrombin inhibitors

Learn How the Ongoing Clinical & Commercial Activities will Affect the Atrial Fibrillation Therapeutic Segment @

Atrial Fibrillation Therapeutics Landscape

There are approx. 15+ key companies developing therapies for Atrial Fibrillation. Currently, Anthos Therapeutics, Inc. is leading the therapeutics market with its Atrial Fibrillation drug candidates in the most advanced stage of clinical development.

The Leading Players in the Atrial Fibrillation Therapeutics Market Include:

  • ARCA biopharma Inc

  • Anthos Therapeutics, Inc.

  • Milestone Pharmaceuticals

  • Armaron Biosciences

  • Ono Pharmaceutical

  • Hanmi Pharmaceutical

  • HUYA Bioscience International

  • Hyloris Pharmaceuticals

  • Vivasc Therapeutics

  • Espero BioPharma

And Many Others

Atrial Fibrillation Emerging and Marketed Drugs Covered in the Report Include:

  • Abelacimab: Anthos Therapeutics, Inc.

  • AGN-151607:AbbVie

  • Botulinum toxin A: Merz Pharma

  • CTP-Amio: Vivasc Therapeutics

  • ESP-001: Espero BioPharma

  • Etripamil: Milestone Pharmaceuticals

  • GENCARO: ARCA biopharma

  • Gencaro: ARCA biopharma

  • HBI-3000: HUYA Bioscience

  • HIP-2001: Hanmi Pharmaceutical

  • HSY 244: Novartis

  • VE 1902: Verseon

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Atrial Fibrillation Current Treatment Patterns

4. Atrial Fibrillation – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Atrial Fibrillation Late Stage Products (Phase-III)

7. Atrial Fibrillation Mid-Stage Products (Phase-II)

8. Atrial Fibrillation Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Atrial Fibrillation Discontinued Products

13. Atrial Fibrillation Product Profiles

14. Key Companies in the Atrial Fibrillation Market

15. Key Products in the Atrial Fibrillation Therapeutics Segment

16. Dormant and Discontinued Products

17. Atrial Fibrillation Unmet Needs

18. Atrial Fibrillation Future Perspectives

19. Atrial Fibrillation Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States